126 related articles for article (PubMed ID: 36156366)
1. Azulene hydrazide-hydrazones for selective targeting of pancreatic cancer cells.
Brogyányi T; Kaplánek R; Kejík Z; Hosnedlová B; Antonyová V; Abramenko N; Veselá K; Martásek P; Vokurka M; Richardson DR; Jakubek M
Biomed Pharmacother; 2022 Nov; 155():113736. PubMed ID: 36156366
[TBL] [Abstract][Full Text] [Related]
2. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells.
Lovejoy DB; Richardson DR
Blood; 2002 Jul; 100(2):666-76. PubMed ID: 12091363
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.
Potuckova E; Jansova H; Machacek M; Vavrova A; Haskova P; Tichotova L; Richardson V; Kalinowski DS; Richardson DR; Simunek T
PLoS One; 2014; 9(2):e88754. PubMed ID: 24586383
[TBL] [Abstract][Full Text] [Related]
4. The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells.
Sahni S; Bae DH; Lane DJ; Kovacevic Z; Kalinowski DS; Jansson PJ; Richardson DR
J Biol Chem; 2014 Apr; 289(14):9692-709. PubMed ID: 24532803
[TBL] [Abstract][Full Text] [Related]
5. The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1).
Chen Z; Zhang D; Yue F; Zheng M; Kovacevic Z; Richardson DR
J Biol Chem; 2012 May; 287(21):17016-17028. PubMed ID: 22453918
[TBL] [Abstract][Full Text] [Related]
6. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
[TBL] [Abstract][Full Text] [Related]
7. Iron chelator-induced up-regulation of Ndrg1 inhibits proliferation and EMT process by targeting Wnt/β-catenin pathway in colon cancer cells.
Chen Z; Sun J; Li T; Liu Y; Gao S; Zhi X; Zheng M
Biochem Biophys Res Commun; 2018 Nov; 506(1):114-121. PubMed ID: 30340826
[TBL] [Abstract][Full Text] [Related]
8. Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites.
Walcourt A; Loyevsky M; Lovejoy DB; Gordeuk VR; Richardson DR
Int J Biochem Cell Biol; 2004 Mar; 36(3):401-7. PubMed ID: 14687919
[TBL] [Abstract][Full Text] [Related]
9. The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.
Lee JC; Chiang KC; Feng TH; Chen YJ; Chuang ST; Tsui KH; Chung LC; Juang HH
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589737
[TBL] [Abstract][Full Text] [Related]
10. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.
Park KC; Geleta B; Leck LYW; Paluncic J; Chiang S; Jansson PJ; Kovacevic Z; Richardson DR
J Biol Chem; 2020 Jan; 295(2):481-503. PubMed ID: 31744884
[TBL] [Abstract][Full Text] [Related]
11. The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity.
Park KC; Dharmasivam M; Richardson DR
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32948029
[TBL] [Abstract][Full Text] [Related]
12. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.
Macková E; Hrušková K; Bendová P; Vávrová A; Jansová H; Hašková P; Kovaříková P; Vávrová K; Simůnek T
Chem Biol Interact; 2012 May; 197(2-3):69-79. PubMed ID: 22521999
[TBL] [Abstract][Full Text] [Related]
13. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
14. Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.
Hrušková K; Potůčková E; Hergeselová T; Liptáková L; Hašková P; Mingas P; Kovaříková P; Šimůnek T; Vávrová K
Eur J Med Chem; 2016 Sep; 120():97-110. PubMed ID: 27187862
[TBL] [Abstract][Full Text] [Related]
15. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer.
Kovacevic Z; Chikhani S; Lovejoy DB; Richardson DR
Mol Pharmacol; 2011 Oct; 80(4):598-609. PubMed ID: 21719465
[TBL] [Abstract][Full Text] [Related]
16. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
17. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway.
Sun J; Zhang D; Zheng Y; Zhao Q; Zheng M; Kovacevic Z; Richardson DR
Mol Pharmacol; 2013 Feb; 83(2):454-69. PubMed ID: 23188716
[TBL] [Abstract][Full Text] [Related]
18. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
19. Mode of action of iron (III) chelators as antimalarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives.
Tsafack A; Loyevsky M; Ponka P; Cabantchik ZI
J Lab Clin Med; 1996 Jun; 127(6):574-82. PubMed ID: 8648262
[TBL] [Abstract][Full Text] [Related]
20. A novel iron chelator that does not induce HIF-1 activity.
Creighton-Gutteridge M; Tyrrell RM
Free Radic Biol Med; 2002 Aug; 33(3):356-63. PubMed ID: 12126757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
